Bayer AG (BAYRY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €bn | 41 | 44 | 51 | 48 | 47 | 44 | 45 | 47 |
| Operating profit | €bn | 7 | 5 | ||||||
| Net profit | €bn | -16 | 1 | 4 | -3 | -3 | -3 | -2 | 5 |
| EPS reported | € | -0.88 | -0.42 | ||||||
| Operating cashflow per share | € | 1.12 | 1.06 | ||||||
| Capex per share | € | 0.61 | 0.69 | ||||||
| FCF per share | € | 0.51 | 0.37 | ||||||
| Free cash flow | €bn | 2 | 1 | ||||||
| Net debt | €bn | 29 | 34 | ||||||
| Book value equity | €bn | 26 | 30 | ||||||
| Book value per share | € | 6.60 | 7.53 | ||||||
| Number of shares | m | 3,929.68 | 3,929.7 | ||||||
| DPS (TTM paid) | € | 0.03 | 0.03 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.40 | 1.22 | ||||||
| P/S LTM | x | 0.83 | 0.80 | ||||||
| P/FCF LTM | x | 18.08 | 54.55 | ||||||
| EV/EBITDA LTM | x | 6.33 | 7.26 | ||||||
| EV/Sales LTM | x | 1.53 | 1.81 | ||||||
| Earnings Yield LTM | % | -9.61% | -3.62% | ||||||
| FCF Yield | % | +5.53% | +1.83% | ||||||
| Quality | |||||||||
| ROE | % | -13.41% | -6.10% | ||||||
| ROIC | % | +7.99% | +7.54% | ||||||
| Operating margin | % | +15.26% | +13.67% | ||||||
| Gross margin | % | +59.21% | +59.05% | ||||||
| FCF/Sales | % | +4.57% | +3.20% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -6.07% | -2.40% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -56.39% | -85.55% | ||||||
| Operating Profit Growth | % | +100.77% | +56.21% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.34% | +0.23% | ||||||
| Dividend Growth | % | +0.19% | +0.19% | ||||||
| Payout Ratio | % | -3.53% | -6.36% | ||||||
| FCF/Debt | x | 0.05 | 0.02 | ||||||
| Net Debt/EBITDA | x | 2.91 | 6.72 | ||||||
| EBIT/Net interest | x | 4.04 | 2.43 | ||||||
| Net debt/market cap | % | +1.01% | +80.08% | ||||||
| Net debt/Equity | x | 1.10 | 1.15 | ||||||
| Gross debt/equity | x | 1.44 | 1.30 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free